Citations

Showing 10 of 108083 citations.

Weathering the storm: a single-institution experience with paroxysmal sympathetic hyperactivity after brain tumor resection in pediatric patients
Bouchal, Samantha M. , Naylor, Ryan M. , Bouchal, Samantha M , Daniels, David J.

Mayo Clinic

Journal of Neurosurgery: Pediatrics | January 6, 2023 | Volume: 31 | Issue: 4 | Pages: 282-289

10.3171/2022.12.peds22369 | PMID 36609373 Get It

OBJECTIVE Paroxysmal sympathetic hyperactivity (PSH) is a complication of severe traumatic or hypoxic brain injury characterized by transient episodes of tachycardia, tachypnea, hypertension, hyperthermia, diaphoresis, and/or dystonic posturing. Posttraumatic "sympathetic storms" are associated with poor outcomes. PSH rarely occurs after brain tumor resection in pediatric patients; only 4 cases have been published since 1929. Thus, the authors sought to report their experience with postcraniotomy PSH in pediatric brain tumor patients. METHODS A retrospective study of patients younger than 18 years of age who underwent craniotomy for brain tumor resection at a single center by a single surgeon over a 7-year period was performed. A clinical diagnosis of postoperative PSH was recorded. Recorded outcomes included the interval between surgery and initiation of cytotoxic therapy, need for long-term CSF diversion, length of hospital stay, and survival. RESULTS Of the 150 patients who were included for analysis, 4 patients were diagnosed with postoperative PSH for an overall occurrence of 2.7%. PSH patients were younger than non-PSH patients (1.8 ± 0.4 years vs 9.2 ± 5.3 years, p = 0.010) and tended to have intraventricular tumors close to the thalamus, basal ganglia, and/or brainstem. PSH patients experienced longer hospital admissions (44.3 ± 23.4 days vs 6.8 ± 9.4 days, p = 0.001), a shorter interval between surgery and initiation of cytotoxic cancer-directed therapy (14.3 ± 8.0 days vs 90.7 days ± 232.9 days, p = 0.011), and increased need for long-term CSF diversion compared with non-PSH patients (75% vs 25%, p = 0.005). At the last follow-up, 50% of PSH patients had died compared with 13% of non-PSH patients (p = 0.094). CONCLUSIONS PSH is a rare postoperative complication that may affect young children with periventricular tumors and is associated with poorer clinical outcomes. Increasing awareness of this condition is vital to improving patient outcomes.
Creutzfeldt–Jakob Disease Misdiagnosed as Multiple System Atrophy
Martin, Nicholas B. , Koga, Shunsuke , Sekiya, Hiroaki , Dickson, Dennis W. , Dickson, Dennis W , Koga, Shunsuke , Sekiya, Hiroaki , Appleby, Brian S.

Mayo Clinic

Movement Disorders Clinical Practice | January 6, 2023 | Volume: 10 | Issue: 3 | Pages: 496-500

10.1002/mdc3.13654 | PMID 36949796 Get It

AbstractBackgroundMultiple system atrophy (MSA) is a progressive neurodegenerative disorder characterized by various combinations of autonomic failure, parkinsonism, and cerebellar syndromes. Although consensus criteria have been widely used to diagnose MSA, accurate clinical diagnosis remains challenging. Other neurodegenerative disorders, such as Lewy body disease, can mimic MSA.ObjectivesWe described clinical and neuropathologic findings of two patients with Creutzfeldt–Jakob disease (CJD) who had antemortem clinical diagnoses of MSA.MethodsThe brain bank for neurodegenerative disorders was queried for cases with a clinical diagnosis of MSA, but neuropathologic findings of CJD.ResultsCase 1 was a 55‐year‐old man with a 6‐month history of orthostatic hypotension, parkinsonism, cerebellar ataxia, bradyphrenia, and memory impairment. Case 2 was a 65‐year‐old man who had a 5‐year history of cerebellar ataxia, parkinsonism, and cognitive impairment, as well as a 7‐year history of dream enactment behavior. Neither case had characteristic α‐synuclein immunoreactive neuronal or glial inclusions typical of MSA. Instead, they had spongiform encephalopathy with neuronal loss and gliosis with prion protein‐immunoreactive kuru‐like plaques. Genetic analyses in case 1 had wild‐type PRNP, whereas case 2 revealed a 4‐octapeptide repeat insertion in PRNP.ConclusionsEven when clinical features suggest MSA, CJD should also be considered if the progression is rapid or the disease course is atypical, such as the absence of autonomic dysfunction for an extended period.
Expanding the spectrum of KIF5A mutations—case report of a large kindred with familial ALS and overlapping syndrome
Dulski, Jarosław , Strongosky, Audrey , Al‐Shaikh, Rana Hanna , Strongosky, Audrey J, Dulski, Jaroslaw , Wszołek, Zbigniew K.

Mayo Clinic

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration | January 6, 2023 | Volume: 24 | Issue: 3-4 | Pages: 347-350

10.1080/21678421.2022.2164204 | PMID 36604770 Get It

A Novel Hair Restoration Technology Counteracts Androgenic Hair Loss and Promotes Hair Growth in A Blinded Clinical Trial
Thor, Dominik, Pagani, Andrea , Bukowiecki, Julia, Houschyar, Khosrow Siamak , Kølle, Stig-Frederik Trojahn , Wyles, Saranya P. , Duscher, Dominik

Mayo Clinic

Journal of Clinical Medicine | January 6, 2023 | Volume: 12 | Issue: 2 | Pages: 470

10.3390/jcm12020470 | PMID 36675398 Get It

Androgenic alopecia (AGA) is a genetically predetermined condition that occurs as a result of stepwise miniaturization of the dermal papilla. During this process, the hair follicle suffers from increasing malnutrition and eventually dies, causing progressive hair loss. We recently highlighted that HIF-1α modulation may counteract hair loss. Here, we aim to demonstrate the positive influence of Tomorrowlabs HIF strengthening factor [HSF] hair restoration technology on hair biology in a monocentric blinded clinical trial over a total period of 9 months. A trial with 20 subjects (4 female and 16 male) and once-daily application of [HSF] hair restoration technology to the scalp was conducted. To assess the tolerability and efficacy of [HSF], testing included dermatological assessment, determination of hair loss by counting after combing, macro images of the head and TrichoScan evaluation of hair density as well as the proportion of anagen hair versus telogen hair. The clinical data show Tomorrowlabs [HSF] hair restoration to be safe and effective to counteract AGA. The use of Tomorrowlabs [HSF] hair restoration resulted in improvements in the clinical parameters of hair quality such as thickness (+7.2%), hair density (+14.3%) and shine and elasticity (+20.3%) during the test period. The effectiveness of the test product was further determined by a significant reduction in hair loss of an average of 66.8% in treatment-responsive subjects after 6 months and an increase in hair growth reaching up to 32.5%, with an average percentage change of 8.4% in all participants and 10.8% in the responsive patients (85% of the study cohort) after 9 months on TrichoScan evaluation. The hair growth cycle was harmonized with the result of an average anagen hair percentage increase of +8.0% and telogen hair percentage reduction of −14.0% shown in the test area. Applicable for both sexes in an alcohol-free formulation, beneficial to scalp health and free of complications or side effects, this novel product provides objectively measurable results counteracting hair loss paired with an improved look and feel of the hair.
Lipoprotein Lipase-Mediated Fatty Acid Metabolism in the Splanchnic Bed
Basu, Rita , Johnson, Carla, Roesner, J.C., Rizza, R. A., Nelson, R.H., Roesner, J. C., Miles, John J.

Mayo Clinic

Journal of Investigative Medicine | January 6, 2023 | Volume: 54 | Issue: 1_suppl | Pages: 135-135

10.1177/108155890605401s207 Get It

Human Heart
Miles, J.M., Nelson, R.H., Prasad, A., Lerman, A., Prasad, Amarendra N., Lerman, Amir

Mayo Clinic

Journal of Investigative Medicine | January 6, 2023 | Volume: 54 | Issue: 1_suppl | Pages: 135-135

10.1177/108155890605401s206 Get It

Proton Magnetic Resonance Spectroscopy at Term Age is Not Predictive of Neurodevelopmental Outcome in Very Low Birth Weight Preterm Infants
Brussel, E.M. Van, Barnes, Pat, Sutcliffe, Trenna L., Dermon, J. D., Ariagno, Ron, Brussel, E. M. Van, Mirmiran, Majid , Spielman, Daniel M.

Mayo Clinic

Journal of Investigative Medicine | January 6, 2023 | Volume: 54 | Issue: 1_suppl | Pages: 128-128

10.1177/108155890605401s162 Get It

The Prevalence of Neuropsychiatric Symptoms in Mild Cognitive Impairment: A Population-Based Study
Rocca, W. A., Knopman, David S., Roberts, Rosebud O., Petersen, Ronald , Geda, Yonas E.

Mayo Clinic

Journal of Investigative Medicine | January 6, 2023 | Volume: 54 | Issue: 2_suppl | Pages: 375-375

10.1177/108155890605402s95 Get It

Cardiovascular Modulation of Dietary Sodium Restriction and β 2 -Adrenergic Receptor Polymorphism in Humans
Eisenach, John H., Pike, Tasha L., Schrage, William G. , Snyder, Eric M., Johnson, Bryana, Turner, S. T. , Joyner, M. J., Schroeder, Darrell R. , Johnson, C.P.

Mayo Clinic

Journal of Investigative Medicine | January 6, 2023 | Volume: 54 | Issue: 2_suppl | Pages: 375-375

10.1177/108155890605402s91 Get It

The Relationship between Caffeine and Blood Pressure in Preadolescent African American Girls
Reddy, Jaishnav, Ebbert, Jon O. , Klesges, Robert C., McClanahan, Barbara S. , Klesges, Lisa M. , Enders, Felicity , Lanctot, Jennifer Q.

Mayo Clinic

Journal of Investigative Medicine | January 6, 2023 | Volume: 54 | Issue: 2_suppl | Pages: 383-383

10.1177/108155890605402s136 Get It